Inquest FMT
Reading File
Finding Sources
Finding Sources
Searching PubMed
"fecal microbiota transplantation" AND "Clostridioides difficile"
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple textbooks. Let me compile a thorough answer on FMT.
Fecal Microbiota Transplant (FMT)
Definition
FMT is the transfer of processed stool from a healthy screened donor into the gastrointestinal tract of a recipient, with the goal of restoring a disrupted (dysbiotic) gut microbiome. It is distinct from simple probiotic supplementation in that it reconstitutes the full complexity of a healthy donor's microbial community.
Rationale / Mechanism
In Clostridioides difficile infection (CDI), the normal protective colonic microbiota is depleted (usually by antibiotics), leaving the colon vulnerable to colonization and replication of C. difficile. FMT reimplants donor bacteria - particularly bacteria resistant to C. difficile colonization - to restore gut biodiversity and the colonization resistance that prevents pathogen overgrowth. Beyond CDI, the intestinal microbiome plays a broad role in inflammation, barrier integrity, and immune regulation; FMT is therefore being explored in many conditions where the microbiome is disrupted.
Indications
Established
- Recurrent/refractory CDI - the primary approved indication. Current guidelines recommend FMT for patients with multiple recurrences of CDI in whom antibiotic treatment has failed (Sabiston Textbook of Surgery).
- Used specifically for second or subsequent recurrences, alongside fidaxomicin or vancomycin ± rifaximin.
- Also considered in recurrences presenting with fulminant disease (on top of standard antibiotic regimens).
Investigational / Emerging
- Inflammatory bowel disease (IBD) - improved remission rates and symptom improvement seen in studies.
- Severe alcoholic hepatitis (AH) - a pilot study found FMT was associated with lower mortality compared with historical controls in severe AH (Yamada's Gastroenterology).
- Sepsis / Critical illness - in preclinical models, FMT improved intestinal barrier integrity and reduced mortality; case series document benefit in critically ill patients, but data are preliminary.
- Melanoma / Immunotherapy resistance - FMT from appropriate donors may help overcome resistance to immune checkpoint inhibitors (Goodman & Gilman's).
Routes of Administration
| Route | Notes |
|---|---|
| Colonoscopic (lower route) | Most effective; allows direct colonic delivery |
| Rectal enema | Lower route; less invasive than colonoscopy |
| Nasogastric / nasoduodenal tube | Upper route; less effective than lower approaches |
| Oral capsules (frozen) | Lyophilized/frozen fecal microbial capsules; convenient; growing evidence |
A comparison of upper vs. lower delivery methods demonstrated lower approaches (colonoscopic/enema) are more effective than upper approaches (Sabiston).
Efficacy
- Efficacy for CDI ranges from 77% to 100%.
- Multiple FMTs may be needed to achieve a good clinical response.
Safety Concerns
- Iatrogenic infection - there have been documented cases of iatrogenic colitis after FMT caused by enteropathogenic E. coli and Shiga toxin-producing E. coli. This underscores the importance of rigorous donor screening.
- Transmission of other pathogens from donor (bacterial, viral, parasitic) is a recognized risk.
- Regulatory bodies (including the FDA) now oversee FMT as a biologic product.
Position in CDI Treatment Algorithm
| Disease Stage | Treatment |
|---|---|
| First episode | Oral vancomycin 125 mg QID × 10 days OR fidaxomicin 200 mg BD × 10 days |
| First episode - fulminant | Vancomycin 500 mg QID ± IV metronidazole |
| First recurrence | Pulsed-tapered vancomycin OR fidaxomicin |
| Second/subsequent recurrence | Fidaxomicin, vancomycin ± rifaximin, or FMT |
| Fulminant with recurrence | Standard antibiotics + consider FMT |
(Based on Sabiston Textbook of Surgery and Current Surgical Therapy 14e)
Monoclonal Antibodies (Adjunct)
Bezlotoxumab (anti-toxin B) and actoxumab (anti-toxin A) are monoclonal antibodies used as co-adjuvant treatment with antimicrobials to prevent CDI recurrence - particularly useful in Ribotype 027 infection, severe CDI, and immunocompromised patients.
Recent Evidence (2023-2026)
- A 2026 systematic review and meta-analysis (PMID 41543263) on oral microbiome therapy (including FMT capsules) for recurrent CDI confirms safety and efficacy.
- A 2024 systematic review in children (PMID 38391047) supports FMT use in pediatric CDI.
- A 2025 meta-analysis (PMID 40542451) shows engrafting gut bacteriophages from FMT donors may modulate microbial metabolism, shedding light on non-bacterial mechanisms of FMT action.
Key sources:
- Sabiston Textbook of Surgery (Fecal Microbiota Transplant section, block 22)
- Current Surgical Therapy 14e (CDI Management)
- Yamada's Textbook of Gastroenterology 7e (Alcoholic Hepatitis Treatment)
- Washington Manual of Medical Therapeutics (Infectious Diarrhea)
- Goodman & Gilman's Pharmacological Basis of Therapeutics (Immunotherapy & FMT)
This is a shared conversation. Sign in to Orris to start your own chat.